BIONEXUS GENE LAB CORP.
Level 8, Tower 8, Avenue 5, The Horizon
Bangar South
No. 8 Jalan Kerinchi
59200 Kuala Lumpur
Malaysia
April 2, 2019
Via EDGAR
SECURITIES AND EXCHANGE COMMISSION
Securities and Exchange Commission
Attn: Mr. Ruairi Regan
Division of Corporate Finance
Washington DC 20549
Re: BioNexus Gene Lab Corporation
File No. 333-229399
Dear Mr. Regan:
BioNexus Gene Lab Corporation hereby requests, pursuant to Rule 461 under the Securities Act of 1933, as amended, that the above-referenced registration statement be accelerated to 4:00 PM, Eastern Time, on Wednesday, April 3, 2019, or as soon thereafter as practicable.
The Company hereby acknowledges that:
° | should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
° | the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
° | the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
If you have any questions concerning this matter, please contact Daniel H. Luciano, Esq., counsel for the Company.
Sincerely,
BioNexus Gene Lab Corporation
/s/ Chi Yuen Leong
Chi Yuen Leong
President
